Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was $59.76 for the day, up 32.89% from the previous closing price of $44.97. In other words, the price has increased by $32.89 from its previous closing price. On the day, 3.56 million shares were traded. TNXP stock price reached its highest trading level at $61.1999 during the session, while it also had its lowest trading level at $42.12.
Ratios:
Our analysis of TNXP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.22 and its Current Ratio is at 7.53. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 15 ’25 when LEDERMAN SETH bought 4,000 shares for $21.55 per share. The transaction valued at 86,200 led to the insider holds 4,005 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 439666272 and an Enterprise Value of 198237408. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.29 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 19.743 whereas that against EBITDA is -2.851.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.91, which has changed by 0.19519997 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $130.00, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is 47.70%, while the 200-Day Moving Average is calculated to be 128.69%.
Shares Statistics:
TNXP traded an average of 1.25M shares per day over the past three months and 1608210 shares per day over the past ten days. A total of 7.55M shares are outstanding, with a floating share count of 7.35M. Insiders hold about 0.07% of the company’s shares, while institutions hold 9.17% stake in the company. Shares short for TNXP as of 1753920000 were 1206311 with a Short Ratio of 0.97, compared to 1751241600 on 1209305. Therefore, it implies a Short% of Shares Outstanding of 1206311 and a Short% of Float of 16.399999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of Tonix Pharmaceuticals Holding Corp (TNXP).The consensus estimate for the next quarter is -$3.05, with high estimates of -$3.05 and low estimates of -$3.05.
Analysts are recommending an EPS of between -$10.3 and -$10.3 for the fiscal current year, implying an average EPS of -$10.3. EPS for the following year is -$4.59, with 2.0 analysts recommending between -$4.5 and -$4.67.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $4.7M to a low estimate of $2.5M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.82MFor the next quarter, 3 analysts are estimating revenue of $3.82M. There is a high estimate of $5.05M for the next quarter, whereas the lowest estimate is $2.8M.
A total of 3 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $14.88M, while the lowest revenue estimate was $10.5M, resulting in an average revenue estimate of $11.99M. In the same quarter a year ago, actual revenue was $10.09MBased on 3 analysts’ estimates, the company’s revenue will be $81.7M in the next fiscal year. The high estimate is $166.1M and the low estimate is $31.3M.
